Telerehabilitation: A Practical Remote Alternative for Coaching and Monitoring Physical Kinetic Therapy in Patients with Mild and Moderate Disabling Parkinson’s Disease during the COVID-19 Pandemic
Table 2
Clinical characteristics and profile of administered anti-Parkinsonian drugs.
N
Gender
Age
Weight (kg)
Height (cm)
BMI
PD years
HY
Mini-Cog
Medication (mg/day)
LEDD (mg)
1
M
70
76
160
29.7 (ow)
12
3
5
LD (750) PR(2.1) RA (1)
1110
2
M
63
75
160
29.3 (ow)
4
2
5
LD (600) RA (1)
700
3
M
70
63
167
22.6
6
2
5
LD (750) PR (0.18) RA (1)
868
4
F
68
68
168
24.4
11
2.5
5
LD (800) RA (1) RO (4)
980
5
F
58
67
167
24
11
2
5
LD (800) PR (1.06)
906
6
M
66
69
166
23.1
3
2.5
5
LD (475) RO (24)
955
7
M
66
65
172
22
6
2.5
5
LD (600) RA (1) RO (4)
555
8
M
70
70
165
25.7 (ow)
12
2.5
5
LD (600) PR (2.1) RA (1)
910
9
F
59
90
173
30.1 (mo, cl-1)
8
2
5
LD (600) PR (2.1) RA (1)
910
10
M
70
81
180
25 (ow)
9
2.5
5
LD (600) PR(0.52) RA(1) AM (100)
852
11
M
54
68
167
24.4
7
2.5
5
RA (1) RO (16)
420
12
F
70
68
160
26.6 (ow)
2
1.5
5
PR (0.52)
52
13
M
69
75
170
26.0 (ow)
5
2
5
LD (200) RA (1) RO (8)
460
14
F
67
75
152
25.4 (ow)
10
2.5
5
LD (800) PR (0.26) RA (1) AM (200)
1126
15
M
67
81
169
25.4 (ow)
3
2
5
LD (500) PR (1.58)
658
16
M
64
94
190
26.0 (ow)
3
2.5
5
LD (800) PR (0.52)
852
17
M
70
92
172
31.1 (mo, cl-1)
12
2.5
5
LD (800) RA (1)
900
Average
65.9 ± 4.87 years
75.1 (±9.6) kg
168.2 (±8.5) cm
25.92 (±2.6)
7.3 ± 3.6 years
2.3 ± 0.35
5
—
777 (±275) mg
Limits
54–70 years
65–92 kg
152–190 cm
22–31.1
3–12 years
1.5–3
—
52–1126 mg
HY = Hoehn and Yahr stage; AM = amantadine; LD = levodopa; PR = pramipexole; RA = rasagiline; RO = ropinirole; LEDD = L-dopa equivalent daily dose (mg/day); ow = overweight; mo, cl 1 = moderate obesity, class I.
